AIMS: The study tested whether high-density lipoprotein-cholesterol (HDL-C) has an effect on percutaneous coronary intervention (PCI)-induced myocardial infarction and its prognosis. Elevation of cardiac troponin I (cTnI) > 3x upper normal limit after PCI is defined as PCI-related myocardial infarction (PMI) and is associated with a negative prognosis. No data exist on the relationship of HDL-C to PMI and PMI-related outcome. METHODS AND RESULTS: Pre-procedural HDL-C levels and post-procedural peak cTnI levels were collected in 350 patients undergoing PCI. Data were analysed for PMI and for acute myocardial infarction (AMI) during follow-up. Patients with PMI (n = 115) had lower HDL-C levels than patients without PMI [n = 235; 1.17 mmol/L (0.75-2.51) vs. 1.27 mmol/L (0.70-2.87), P < 0.001]. Pre-procedural HDL-C levels were inversely related to the occurrence of PMI [odds ratio for PMI: 0.884, 95% CI: 0.80, 0.98; P = 0.02 for an HDL-C-increment of 5 mg/dL (0.13 mmol/L)] and to AMI during follow-up [hazard ratio (HR): 0.697, 95% CI: 0.54, 0.90; P = 0.005]. The occurrence of PMI was associated with an elevated HR for AMI (4.702, 95% CI: 1.79, 12.37; P = 0.002). Low-risk levels of pre-procedural HDL-C [men >or=40 mg/dL (>or=1.03 mmol/L), women >or=45 mg/dL (>or=1.16 mmol/L)] did not influence the negative effects of PMI on outcome (HR: 5.510, 95% CI: 1.43, 21.31; P = 0.013) and reduction of AMI-free survival [mean AMI-free survival time with PMI: 1167.5 days (95% CI: 1098.27, 1236.67) vs. 1240.7 days (95% CI: 1220.94, 1290.49) without PMI; log-rank P = 0.005]. Conclusion Small increases in HDL-C in patients undergoing elective PCI convert into a substantial reduction of risk for PMI, which has adverse effects on the long-term prognosis. Patients with PMI are at a high risk for AMI at any HDL-C level and therefore should receive particular monitoring by the treating physician over a long period after PCI.
AIMS: The study tested whether high-density lipoprotein-cholesterol (HDL-C) has an effect on percutaneous coronary intervention (PCI)-induced myocardial infarction and its prognosis. Elevation of cardiac troponin I (cTnI) > 3x upper normal limit after PCI is defined as PCI-related myocardial infarction (PMI) and is associated with a negative prognosis. No data exist on the relationship of HDL-C to PMI and PMI-related outcome. METHODS AND RESULTS: Pre-procedural HDL-C levels and post-procedural peak cTnI levels were collected in 350 patients undergoing PCI. Data were analysed for PMI and for acute myocardial infarction (AMI) during follow-up. Patients with PMI (n = 115) had lower HDL-C levels than patients without PMI [n = 235; 1.17 mmol/L (0.75-2.51) vs. 1.27 mmol/L (0.70-2.87), P < 0.001]. Pre-procedural HDL-C levels were inversely related to the occurrence of PMI [odds ratio for PMI: 0.884, 95% CI: 0.80, 0.98; P = 0.02 for an HDL-C-increment of 5 mg/dL (0.13 mmol/L)] and to AMI during follow-up [hazard ratio (HR): 0.697, 95% CI: 0.54, 0.90; P = 0.005]. The occurrence of PMI was associated with an elevated HR for AMI (4.702, 95% CI: 1.79, 12.37; P = 0.002). Low-risk levels of pre-procedural HDL-C [men >or=40 mg/dL (>or=1.03 mmol/L), women >or=45 mg/dL (>or=1.16 mmol/L)] did not influence the negative effects of PMI on outcome (HR: 5.510, 95% CI: 1.43, 21.31; P = 0.013) and reduction of AMI-free survival [mean AMI-free survival time with PMI: 1167.5 days (95% CI: 1098.27, 1236.67) vs. 1240.7 days (95% CI: 1220.94, 1290.49) without PMI; log-rank P = 0.005]. Conclusion Small increases in HDL-C in patients undergoing elective PCI convert into a substantial reduction of risk for PMI, which has adverse effects on the long-term prognosis. Patients with PMI are at a high risk for AMI at any HDL-C level and therefore should receive particular monitoring by the treating physician over a long period after PCI.
Authors: Giuseppe Lippi; Claudia Lo Cascio; Giorgio Brocco; Elisa Danese; Martina Montagnana; Antonella Bassi; Beatrice Caruso; Chiara Bovo; Gian Luca Salvagno Journal: Ann Transl Med Date: 2016-05
Authors: Josef Veselka; Petr Hájek; Martin Malý; David Zemánek; Radka Adlová; Pavol Tomašov; Lucie Martinkovičová; David Tesař; Pavel Cervinka Journal: Arch Med Sci Date: 2011-03-08 Impact factor: 3.318
Authors: Martin Houde; Adel Schwertani; Hanène Touil; Louisane Desbiens; Otman Sarrhini; Roger Lecomte; Martin Lepage; Hugo Gagnon; Shinji Takai; Gunnar Pejler; Danielle Jacques; Fernand Gobeil; Robert Day; Pedro D'Orléans-Juste Journal: Front Pharmacol Date: 2018-08-31 Impact factor: 5.810
Authors: Hector A Cabrera-Fuentes; Corina Alba-Alba; Julian Aragones; Jürgen Bernhagen; William A Boisvert; Hans E Bøtker; Gabriela Cesarman-Maus; Ingrid Fleming; David Garcia-Dorado; Sandrine Lecour; Elisa Liehn; Michael S Marber; Nephtali Marina; Manuel Mayr; Oscar Perez-Mendez; Tetsuji Miura; Marisol Ruiz-Meana; Eduardo M Salinas-Estefanon; Sang-Bing Ong; Hans J Schnittler; Jose T Sanchez-Vega; Adriana Sumoza-Toledo; Carl-Wilhelm Vogel; Dina Yarullina; Derek M Yellon; Klaus T Preissner; Derek J Hausenloy Journal: Basic Res Cardiol Date: 2015-12-14 Impact factor: 17.165